DRKS00026662RecruitingNot Applicable
Prospective evaluation of the safety and efficacy of MR-guided single-fraction stereotactic ablative radiotherapy for inoperable peripheral lung tumors - SINGLE SHOT - SINGLE SHOT LUNG
Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LM0 sites25 target enrollmentStarted: November 8, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •1. histologically confirmed inoperable peripheral NSCLC < 2 cm in diameter and > 1 cm from the thoracic wall.
- •2. histologically confirmed metastatic malignant disease with pulmonary metastases. Biopsy of lung metastasis is not required. Total number of lung metastases of 1-3, not centrally located, with a maximum diameter of = 3 cm each.
- •3. Age over 18 years
- •4. ECOG Performance Status 0-2
- •5. Previous surgery, systemic and local ablative therapies (RFA, SABR, brachytherapy, etc.) are allowed.
- •6. Indication for radiotherapy confirmed at the multidisciplinary tumor board.
- •7. Patients are able to understand and willing to sign an IRB-approved informed consent document and adhere to the conditions of the study.
Exclusion Criteria
- •1. Known contraindications for radiotherapy e.g. severe comorbidities, interstitial lung disease etc.
- •2. Systemic therapies (cytotoxic or targeted therapies incl. immune checkpoint inhibitors) are paused during radiotherapy (however, allowed in individual cases with high tumor burden after internal discussions at the Department of Radiation Oncology, University Hospital LMU Munich.
- •3. Significant overlap with a previously treated radiation volume - prior radiotherapy is generally allowed as long as all dose requirements are met in the composite plan (biologically effective doses are calculated for this purpose).
- •4. Pregnant and/or breastfeeding.
- •5. Medical or psychological impairments that do not allow proper informed consent or trial participation.
- •6. Lack of legal capacity.
Investigators
Similar Trials
Recruiting
Not Applicable
Prospective evaluation of the safety and efficacy of MR-guided single-fraction stereotactic ablative radiotherapy for unresectable primary or secondary liver tumors - SINGLE SHOT LIVERC22C78.7Malignant neoplasm of liver and intrahepatic bile ductsSecondary malignant neoplasm of liver and intrahepatic bile ductDRKS00027117Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LMU München35
Recruiting
Not Applicable
Prospective evaluation of the safety and efficacy of MR-guided moderately hypofractionated radiotherapy for inoperable malignant tumors of the lung, pleura, and mediastinum with a diameter > 5 cm and poor risk factors - MR-HYPOLUNGC34Malignant neoplasm of bronchus and lungDRKS00026665Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LM10
Active, not recruiting
Phase 1
Evaluation of the efficacy and safety of topical treatment on clinical signs and symptoms of dry eye disease associated with moderate meibomian gland dysfunction”EUCTR2021-003469-36-ESaboratorios Théa, S.A.54
Completed
Not Applicable
Prospective evaluation of the efficacy and safety of a dermal filler familyL80-L99Other disorders of the skin and subcutaneous tissueDRKS00025937niCare GmbH137
Active, not recruiting
Phase 1
MSC as therapy for INS: phase 1 studyEUCTR2016-004804-77-ITBAMBINO GESU' CHILDREN'S HOSPITA20